Los últimos desarrollos de investigación, actualizaciones de ensayos clínicos y noticias regulatorias de la comunidad científica de péptidos.
Lean mass loss is an increasingly important endpoint in GLP-1 class drug research. We review the current data on what proportion of weight lost is fat vs muscle, and what the research implications are for combination approaches.
The combination of a GHRH analogue and a GHRP creates a synergistic GH secretagogue profile that neither compound achieves alone. We examine the mechanistic rationale and what preclinical combination data shows for CJC-1295 and Ipamorelin.
With semaglutide and tirzepatide now mainstream, the research community has turned its focus to longer-acting, more selective, and multi-receptor peptide agonists. We map the current frontier.
Todo el contenido es exclusivamente para fines científicos y educativos. Los péptidos de investigación son solo para uso en laboratorio y no para consumo humano.
